Sanofi Updates Rare Disease Pipeline, Shares Mixed Reaction from Investors.

Sanofi reported phase 3 success for venglustat in treating type 3 Gaucher disease and plans to pursue global regulatory filings. The company recorded mixed late-stage results for venglustat in Fabry disease and received a positive opinion for conditional marketing authorisation of Rezurock for chronic graft versus host disease in the EU. This cluster of updates arrives with shares trading at €81.09, up 5.2% over the past week, and a 1 year return of 18.4% decline and a 5 year return of 27.0%. Investors will watch how upcoming regulatory decisions and further data in Fabry disease influence the company's portfolio balance and potential revenue mix.